New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:10 EDTACTActavis announces final stockholder results in Forest Laboratories acquisition
Actavis announced the final results of the elections made by stockholders of Forest Laboratories as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest. Holders of approximately 13.81% of the outstanding shares of Forest common stock elected to receive 3306 of an Actavis ordinary share and $26.04 in cash, without interest, with fractions of an Actavis ordinary share being cashed out at $219.00 per Actavis ordinary share. Holders of approximately 0.44% of the outstanding Forest shares elected to receive $86.81 in cash, without interest. Holders of approximately 72.78% of the outstanding shares of Forest common stock elected to receive $25.67 in cash plus 0.3326 of an Actavis ordinary share, with fractions of an Actavis ordinary share being cashed out at $219.00. Holders of approximately 12.97% of the outstanding Forest shares failed to make a valid election or did not deliver a valid election form prior to the deadline and will receive the Standard Election Consideration for each Actavis ordinary share, with fractions of an Actavis ordinary share being cashed out at $219.00 per Actavis ordinary share.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:27 EDTACTActavis' Dalvance shows positive Phase 3 results for skin infections
Actavis announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus. Preliminary top-line data demonstrated the 1500 mg single-dose of Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy. Actavis plans to file a supplemental New Drug Application with these data in Q3.
07:09 EDTACTCipher Pharmaceuticals announces Markman hearing in Absorica patent suit
Subscribe for More Information
April 23, 2015
08:16 EDTACTActavis launches Avycaz anti-infective in U.S.
Subscribe for More Information
April 22, 2015
07:37 EDTACTOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 20, 2015
16:22 EDTACTActavis reports CCO Charles Mayr to retire for health reasons
Subscribe for More Information
08:12 EDTACTActavis's BOTOX label approved by FDA for spasticity treatment
Subscribe for More Information
07:18 EDTACTAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 14, 2015
06:18 EDTACTActavis urges U.S. appeals court to reverse decision on Namenda, AP reports
Subscribe for More Information
April 13, 2015
16:37 EDTACTActavis announces availability of 52mg Liletta to prevent pregnancy
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that Liletta 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.
10:52 EDTACTMeister says Actavis bought great companies, can continue growing
Subscribe for More Information
09:27 EDTACTActavis and Medicine360 announce Liletta es available in the U.S.
Subscribe for More Information
08:34 EDTACTZoetis names Actavis Executive Chairman Paul Bisaro to board
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use